211 related articles for article (PubMed ID: 11110700)
1. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.
Falanga A; Marchetti M; Evangelista V; Vignoli A; Licini M; Balicco M; Manarini S; Finazzi G; Cerletti C; Barbui T
Blood; 2000 Dec; 96(13):4261-6. PubMed ID: 11110700
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.
Falanga A; Marchetti M; Barbui T; Smith CW
Semin Hematol; 2005 Oct; 42(4):239-47. PubMed ID: 16210037
[TBL] [Abstract][Full Text] [Related]
3. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor.
Falanga A; Marchetti M; Evangelista V; Manarini S; Oldani E; Giovanelli S; Galbusera M; Cerletti C; Barbui T
Blood; 1999 Apr; 93(8):2506-14. PubMed ID: 10194429
[TBL] [Abstract][Full Text] [Related]
5. Relationship between elevation in the plasma concentration of elastase-alpha 1 proteinase inhibitor complex (E-alpha 1 PI) and haemostatic parameters during haemodialysis.
Yamazaki M; Asakura H; Saito M; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Aoshima K; Sato T; Tsugawa Y
Blood Coagul Fibrinolysis; 1995 Feb; 6(1):5-10. PubMed ID: 7795153
[TBL] [Abstract][Full Text] [Related]
6. Increased CD11/CD18 expression and altered metabolic activity on polymorphonuclear leukocytes from patients with polycythemia vera and essential thrombocythemia.
Burgaleta C; González N; César J
Acta Haematol; 2002; 108(1):23-8. PubMed ID: 12145463
[TBL] [Abstract][Full Text] [Related]
7. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers.
Slaughter TF; LeBleu TH; Douglas JM; Leslie JB; Parker JK; Greenberg CS
Anesthesiology; 1994 Mar; 80(3):520-6. PubMed ID: 8141448
[TBL] [Abstract][Full Text] [Related]
8. Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera.
Karakantza M; Giannakoulas NC; Zikos P; Sakellaropoulos G; Kouraklis A; Aktypi A; Metallinos IC; Theodori E; Zoumbos NC; Maniatis A
Int J Hematol; 2004 Apr; 79(3):253-9. PubMed ID: 15168594
[TBL] [Abstract][Full Text] [Related]
9. Prothrombin fragments F1+2, thrombin-antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis.
Giannitsis E; Siemens HJ; Mitusch R; Tettenborn I; Wiegand U; Schmücker G; Sheikhzadeh A; Stierle U
Int J Cardiol; 1999 Mar; 68(3):269-74. PubMed ID: 10213277
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the responses of global tests of coagulation with molecular markers of neutrophil, endothelial, and hemostatic system perturbation in the baboon model of E. colisepsis--toward a distinction between uncompensated overt DIC and compensated non-overt DIC.
Wada H; Yamamuro M; Inoue A; Shiku H; Sakuragawa N; Redl H; Peer G; Taylor FB
Thromb Haemost; 2001 Dec; 86(6):1489-94. PubMed ID: 11776318
[TBL] [Abstract][Full Text] [Related]
11. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera.
Falanga A; Marchetti M; Vignoli A; Balducci D; Barbui T
Exp Hematol; 2005 May; 33(5):523-30. PubMed ID: 15850829
[TBL] [Abstract][Full Text] [Related]
12. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.
Cancelas JA; García-Avello A; García-Frade LJ
Thromb Res; 1994 Sep; 75(5):513-20. PubMed ID: 7992252
[TBL] [Abstract][Full Text] [Related]
13. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
14. Markers of activated hemostasis and fibrinolysis in patients with pulmonary malignancies: comparison of plasma levels in central venous and pulmonary venous blood.
Kalweit GA; Feindt P; Micek M; Gams E; Hellstern P
Thromb Res; 2000 Feb; 97(3):105-11. PubMed ID: 10680641
[TBL] [Abstract][Full Text] [Related]
15. Influence of aging on the activity of the hemostatic system: prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years.
Cadroy Y; Pierrejean D; Fontan B; Sié P; Boneu B
Nouv Rev Fr Hematol (1978); 1992; 34(1):43-6. PubMed ID: 1523099
[TBL] [Abstract][Full Text] [Related]
16. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF.
Bellucci S; Ignatova E; Jaillet N; Boffa MC
Thromb Haemost; 1993 Nov; 70(5):736-42. PubMed ID: 8128427
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms.
Cella G; Marchetti M; Vianello F; Panova-Noeva M; Vignoli A; Russo L; Barbui T; Falanga A
Thromb Haemost; 2010 Jul; 104(1):151-6. PubMed ID: 20431848
[TBL] [Abstract][Full Text] [Related]
18. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Marchetti M; Castoldi E; Spronk HM; van Oerle R; Balducci D; Barbui T; Rosing J; Ten Cate H; Falanga A
Blood; 2008 Nov; 112(10):4061-8. PubMed ID: 18768782
[TBL] [Abstract][Full Text] [Related]
19. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
[No Abstract] [Full Text] [Related]
20. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
